Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

xvivo perfusion - XVIPY

XVIPY

Close Chg Chg %
8.55 -0.92 -10.76%

Closed Market

7.63

-0.92 (10.76%)

Volume: 206.00

Last Updated:

May 7, 2025, 1:54 PM EDT

Trade Now

Company Overview: xvivo perfusion - XVIPY

XVIPY Key Data

Open

$7.63

 Day Range

7.63 - 7.63

52 Week Range

7.63 - 12.97

 Market Cap

$986.56M

Shares Outstanding

126.00M

 Public Float

N/A

Beta

2.08

 Rev. Per Employee

N/A

P/E Ratio

75.97

 EPS

$0.10

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

68.05

  

XVIPY Performance

1 Week
 
 -10.76%
 
1 Month
 
 -29.38%
 
3 Months
 
 -41.17%
 
1 Year
 
 N/A
 
5 Years
 
 N/A
 

XVIPY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xvivo Perfusion - XVIPY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
30.10M 41.04M 56.29M 77.79M
Sales Growth
+54.04% +36.34% +37.16% +38.20%
Cost of Goods Sold (COGS) incl D&A
11.82M 13.05M 17.01M 25.68M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.76M 1.56M 2.91M 6.38M
Depreciation
1.29M 1.41M 2.19M 3.07M
Amortization of Intangibles
2.47M 148.91K 716.94K 3.31M
COGS Growth
+81.91% +10.40% +30.43% +50.91%
Gross Income
18.28M 27.99M 39.27M 52.11M
Gross Income Growth
+40.16% +53.11% +40.30% +32.69%
Gross Profit Margin
+60.74% +68.21% +69.77% +66.99%
2021 2022 2023 2024 5-year trend
SG&A Expense
18.79M 26.16M 35.65M 41.18M
Research & Development
3.61M 6.39M 12.18M 10.68M
Other SG&A
15.19M 19.77M 23.47M 30.50M
SGA Growth
+29.13% +39.24% +36.23% +15.52%
Other Operating Expense
- - - -
-
Unusual Expense
2.29M 1.41M 3.63M 2.58M
EBIT after Unusual Expense
(2.80M) 418.58K (3.39K) 8.35M
Non Operating Income/Expense
3.61M 1.89M 9.02M 11.09M
Non-Operating Interest Income
- 209.78K 833.65K 1.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
32.15K 108.10K 112.10K 529.76K
Interest Expense Growth
-47.34% +236.25% +3.69% +372.60%
Gross Interest Expense
32.15K 108.10K 112.10K 529.76K
Interest Capitalized
- - - -
-
Pretax Income
776.38K 2.20M 8.90M 18.91M
Pretax Income Growth
+112.48% +184.00% +303.80% +112.40%
Pretax Margin
+2.58% +5.37% +15.82% +24.31%
Income Tax
(173.22K) 384.09K 254.43K 2.63M
Income Tax - Current - Domestic
(119.05K) 90.42K 1.36M 778.32K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(54.17K) 293.68K (1.10M) 1.85M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
949.60K 1.82M 8.65M 16.29M
Minority Interest Expense
- - - -
-
Net Income
949.60K 1.82M 8.65M 16.29M
Net Income Growth
+119.99% +91.75% +375.01% +88.29%
Net Margin Growth
+3.15% +4.44% +15.37% +20.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
949.60K 1.82M 8.65M 16.29M
Preferred Dividends
- - - -
-
Net Income Available to Common
949.60K 1.82M 8.65M 16.29M
EPS (Basic)
0.0082 0.0154 0.0722 0.1293
EPS (Basic) Growth
+118.76% +87.80% +368.83% +79.09%
Basic Shares Outstanding
115.38M 118.10M 119.74M 126.00M
EPS (Diluted)
0.0082 0.0154 0.0722 0.1286
EPS (Diluted) Growth
+118.76% +87.80% +368.83% +78.12%
Diluted Shares Outstanding
115.74M 118.10M 119.74M 126.60M
EBITDA
3.25M 3.39M 6.53M 17.31M
EBITDA Growth
+5,905.38% +4.31% +92.86% +164.92%
EBITDA Margin
+10.79% +8.26% +11.61% +22.25%

Xvivo Perfusion in the News